Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
ASRT Stock Chart & Stats
$0.80
-$0.03(-3.72%)
At close: 4:00 PM EST
$0.80
-$0.03(-3.72%)
Day’s Range― - ―
52-Week Range$0.51 - $1.16
Previous CloseN/A
Volume363.47K
Average Volume (3M)292.38K
Market Cap
$79.31M
Enterprise Value$9.14M
Total Cash (Recent Filing)$98.18M
Total Debt (Recent Filing)$45.79M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 06, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding96,239,624
10 Day Avg. Volume248,014
30 Day Avg. Volume292,380
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.12
Enterprise Value/Revenue0.08
Enterprise Value/Gross Profit0.11
Enterprise Value/Ebitda-0.50
Forecast
1Y Price Target
$2.50Price Target Upside212.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
EarningsAssertio's total revenue of $29.2M exceeded expectations, showcasing strong performance despite challenges.
Financial StrategyThe company is generating cash and does not require financing, positioning itself for potential transformative growth.
Product GrowthSympazan is currently the only FDA-approved oral film formulation of clobazam, a commonly used benzodiazepine, for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients two years of age or older.
Bears Say
Financial PerformanceThe company recorded a 2Q25 net loss of $0.17 vs. the original forecast for a net loss of only $0.10 per share.
Market CompetitionRisks include inability to obtain additional market share for ROLVEDON and Sympazan.
Revenue ForecastThe full-year 2026 top-line estimate has been reduced to $115M from the prior $135.6M, which reflects modulated expectations for Assertio's legacy products.
Assertio Therapeutics News
ASRT FAQ
What was Assertio Therapeutics Inc’s price range in the past 12 months?
Assertio Therapeutics Inc lowest stock price was $0.51 and its highest was $1.16 in the past 12 months.
What is Assertio Therapeutics Inc’s market cap?
Assertio Therapeutics Inc’s market cap is $79.31M.
When is Assertio Therapeutics Inc’s upcoming earnings report date?
Assertio Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 18 days.
How were Assertio Therapeutics Inc’s earnings last quarter?
Assertio Therapeutics Inc released its earnings results on Aug 11, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.08.
Is Assertio Therapeutics Inc overvalued?
According to Wall Street analysts Assertio Therapeutics Inc’s price is currently Undervalued.
Does Assertio Therapeutics Inc pay dividends?
Assertio Therapeutics Inc does not currently pay dividends.
What is Assertio Therapeutics Inc’s EPS estimate?
Assertio Therapeutics Inc’s EPS estimate is -0.09.
How many shares outstanding does Assertio Therapeutics Inc have?
Assertio Therapeutics Inc has 96,239,624 shares outstanding.
What happened to Assertio Therapeutics Inc’s price movement after its last earnings report?
Assertio Therapeutics Inc reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went up 13.889%.
Which hedge fund is a major shareholder of Assertio Therapeutics Inc?
Currently, no hedge funds are holding shares in ASRT
Assertio Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.50 (212.50% Upside)
$2.50 (212.50% Upside)
Blogger Sentiment
Bullish
ASRT Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 75.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.03%
12-Months-Change
Fundamentals
Return on Equity
-38.40%
Trailing 12-Months
Asset Growth
-2.03%
Trailing 12-Months
Company Description
Assertio Therapeutics Inc
Assertio Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative therapeutics to address unmet medical needs in pain management and other therapeutic areas. The company's portfolio includes products that leverage its expertise in drug delivery and formulation technologies, with a strong emphasis on prescription medications that provide effective solutions for patients suffering from various conditions.
ASRT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a mix of positive developments such as strong demand for Rolvedon and successful legal settlements, but also faced challenges including a decline in net product sales and the discontinuation of Otrexup commercialization. The company's financial position remains strong, which supports future strategic transactions.View all ASRT earnings summariesASRT Stock 12 Month Forecast
Average Price Target
$2.50
▲(212.50% Upside)
Technical Analysis
Ownership Overview
1.99% Insiders
6.15% Mutual Funds
10.91% Other Institutional Investors
76.53% Public Companies and
Individual Investors